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Abstract: 
This study was carried out to determine the level of expression of tumour 
suppressor gene p53 protein products among different types of lung lesions. 
The aim of this study was to determine a scientific correlation between p5 3 
expression indices and different type of lung lesions. 
A total of 33 paraffin block lung samples of varying histological 
background were selected from Pathology department of three different 
hospitals of Malaysia. These cases comprised of benign lesions like 
malfonnations, emphysema, bronchiactasis, abscess, fungus and malignant 
lesions like different types of lung carcinomas. 
All the samples were submitted for routine Haematoxylin & Eosin (H&E) 
stains and Immunohistochemical (IH C) staining for five mutant and wild 
type of p53 protein products namely DO 1, BP, Phosphatase, 007 and 1801 
purchased from Novocastra company, UK. The indirect IHC techniques 
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were employed. The results were classified high and low level of staining 
using visual analogue scale suggested by Dowell and Hall. Also we 
counted 1 000 cells randomly from the highest area of positive staining and 
counted the number of cells positive for the IH C staining. 
The clinical symptoms found in the record sheet of these 33 patients were 
also analysed and correlated with the histological findings. It was found that 
8(50%) of the positive samples had history of loss of appetite(LOA),Loss of 
weight (LOW) and cough. Haemoptysis was present in 6(37.5%), fever and 
other constitutional symptoms in 3 (18.75%) cases. 2 cases (12.5%) were 
smokers and 2(12.5%) cases were asymptomatic. 
The p53 expression was highest in squamous cell carcinoma (43.75%), 
followed by adenocarcinomas(31.25o/o )and metastatic lesions in lung ( 25o/o ). 
The finding of the present study is similar to other studies which showed that 
the p53 staining was more in squamous cell (epidermoid) carcinoma 16 of 
27(59.22o/o) non small cell carcinoma 22 of 46(47.8%), small cell 
carcinoma 8 of 30(26.6o/o),adenocarcinomas 6 of 19(37.57o/o)2 . 
The result of the present study denotes the squamous malignancy 
as the most common phenotype for p53 positivity in lung samples 
and benign lesions are negative for p53 staining. However, as the 
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sample size of this study is low the results should be interpreted 
cautiously and it is advocated that study with large sample size is 
required to substantiate these findings 
Introduction: 
Oncogene and p53 association 
Oncogenes are genes that cause cancer. P53 is the most commonly mutated 
genes in human cancers. 50% of all human cancer contain cells with point 
mutations or deletions in both alleles ofp53 gene. Over expression ofp53 
oncogenes are found in majority of melanomas, HPV induced cervical 
cancers, breast& colon cancers, some cases of carcinoma of lung, bladder 
.,. 
and thyroid 1• 
The gene for p53 is located in chromosome 17p, a frequent site of 
allele loss in many tumours including breast, colon, brain, lung. 
The p53 over expression is expressed at a level detectable by IHC 
in carcinomas of various sites including breast, colon, bladder and 
tung . Expression has been shown to correlate with poor prognosis 
breast cancer 2'3'4'5• In colonic tumours p53 was expressed in 4 7o/o 
of cancers, 9o/o in adenomas and no expression normal mucosa 6• 
P53 is recognised as the cells policeman and in fact tumour suppressor gene. 
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Loss of genetic informations on chromosome 17p locus where p53 is found 
common in all neoplasia. The most frequent malignancies are malignant 
melanoma(88%), testicular tumour (87%), colorectal carcinoma (58o/o). 
Lower in the list were leukaemias (13%), thyroid tumours(5o/o). 
p53 accumulation was observed in 76% of212 human malignant lesions 
including breast, colon, stomach carcinomas, melanomas, carcinoma of 
testis, urinary bladder carcinoma, uterine carcinoma and soft tissue 
7 
sarcomas . 
P53 is a molecular phospho protein with a molecular weight of 53kDa. 
Wild type is present in wide variety of normal cells, but the protein has a 
very short half life and thus present in only minute amounts, generally below 
the detection level by IHC.Somatic mutation of p53 gene is very frequent 
event in the development of human neoplasia and because mutant p5 3 
proteins often are much more stable than wild type p53 proteins the mutant 
p5 3 accumulates in high level 8· 
The normal p53 protein is unstable and difficult to quantitate . wild type p53 
acts as modulator which can tum cruicial genes either on or off. It also 
inhibits DNA replication ,in the regulation of apoptosis <J. Wild type p53 
behaves as a tumour suppressor ,mutant p53 behaves as a dominant 
transformimg oncogene. The abnormal p53 protein or the mutant p53 is 
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more stable than the wild type. The degraded p53 protein is functional 
equivalence of a mutated p53.This result in abnormal protein accumulating 
to levels where it can be detected by IHC in contrast to normal low levels. 
IHC provides a rapid , economical method for p53 alterations and can be 
used on cytologic, paraffinised and frozen sections 
DNA tumour viruses produces proteins that bind to and functionally 
inactivate p53 protein. Wild type p53 possesses tumour suppressor activity 
while mutant protein does not. Mutant protein can act as a dominant 
transforming element in DNA leading to development of neoplasia. 
Wild type p5 3 can induce cell cycle arrest, mutant type does not. 
P53 is probably is a transcriptional regulator, wild type can bind 
DNA in a sequence specific manner, mutant p53 cannot. 
Abnormalities ofp53 is common in neoplasia Mutation ofp53 
gene is associated with conformational changes and altered 
. b"l" P53 h I . . 9 1 o 11 12 ft . protein a 1 Ity. as a ro e In apoptos1s ' ' ' , a er geno toxJc 
insults. 
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P53 and lung cancer association 
Bronchial carcinogenesis is characterized by accumulated gene 
abnormalities which ultimately leads to malignant transformation 
of bronchial epithelial cells,followed by invasion and metastasis. 
One of the most common and consistant of these genetic lesion is 
inactivation of p53 tumour suppressor gene by mutation and 
deletion.The frequency ofp53 alteration in lung cancer highest in 
these subtypes of bronchial cancers that are most consistently 
associated with smoking ,especially small cell lung carcinoma and 
squamous cell carcinoma. The frequency is lower in 
adencarcinoma in which association with smoking although 
• 13 present IS not as strong . 
In a study of forty nine specimen of non malignant and malignant 
tumour of lung tissue examined for wild type, and mutant type 
p53,bcl-2 and apoptosis. Wild type p53 expression peaked in 
peritumoral and metaplastic samples, mutant p53, bcl-2 and 
7 
apoptosis were first detected in metaplastic lesion and increased 
with progression to carcinoma14• 
P53 tumour suppressor gene play an important role in the 
carcinogenic process of lung carcinoma. The presence of multiple 
mutations in p53 gene may explain higher incidence of lung 
carcinoma in patients with idiopathic pulmonary fibrosis( IPF) 15• 
Also p53 expression was observed significantly more frequently in 
bronchiolar dysplasias with pneumoconiosis 13 of23, than 
patients without pneumoconiosis 9 of 23 16• 
P53 and bcl-2 oncoproteins are detectable immuno electron 
microscopically in lung cancer cells 17• 
Endobronchial carcinoma develops through a continuum of 
morphologically recognizable pre neoplastic changes. No marker 
has been identified that can predict biological behavior of these 
lesions. 39 endobronchial lesions from patients without overt lung 
cancer were analysed by ll-IC for abnormal expression of p53 
protein i.e suprabasal p53 expression. Clear suprabasal 
immunostaining was found in 2(12%) of hyperplastic or squamous 
8 
metaplastic lesions, in 1 ( 10%) of the mildly or moderately 
dysplastic lesion and in 9(75°/o) of the severely _dysplastic or 
carcinoma in situ (CIS) lesion. Suprabasal p53 immunostaining 
was found significantly more frequent in severe dysplasia or CIS 
(p<O.O 1 ).It was concluded that suprabasal p53 staining is 
associated with bronchial cancer and might have additive value to 
predict biologic behavior of pre neoplastic endobronchial lesions 
in the population risk of bronchial cancer18• 
Reviewing all the mentioned literature search results and keeping 
in mind that little work was done and published on p53 expression 
in h\ng samples in Malaysia the present study was undertaken with 
the following objectives: 
1. To form a baseline data for future work in the research of 
lung cancer in Malaysia particularly in relation to p53 
expression. 
2. To identify the common lesions of lung who are p53 positive 
and their clinico pathologic correlation. 
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Methods and Results: 
A total of 33 paraffin block lung samples of varying histological 
background were collected from Pathology department of four different 
hospitals (hospital Kuala Terengganu, pulau Pinang, KotaBharu and USM) 
of Malaysia. These cases comprised of benign lesions like malformations, 
emphysema, bronchiactasis, abscess, fungus and malignant lesions.All the 
samples were submitted for routine Haematoxylin & Eosin (H&E) stains 
and Immunohistochemical (IHC) staining for five mutant and wild type of 
p5 3 protein products namely DO 1, BP, Phosphatase, 007 and 180 1 
purchased from Novocastra company, UK. The indirect IHC techniques 
were employed. The results were classified high and low level of staining 
using visual analogue scale suggested by Dowell and Hall19. Also we 
counted 1000 cells randomly from the highest area of positive staining and 
counted the number of cells positive for the IHC staining. 
The clinical symptoms found in the record sheet of these 33 patients were 
also analysed and correlated with the histological findings. It was found that 
8(50%) of the histologically proven malignant samples had history of loss of 
appetite(LOA),Loss of weight (LOW) and cough. Haemoptysis was present 
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in 6(37.5%), fever and other constitutional symptoms in 3 ( 18.75%) cases. 2 
cases ( 12.5%) were smokers and 2( 12.5%) cases were asymptomatic. The 
results are shown in table I, 2,3,4. 
Table-t 
Showing Final distribution of cases. 
Total no Sex Race Mean age Benign Malignant 
of MaleFemale Malay/Chinese ±SE Lung Lung 
Sam_ples N(%) N(%) Lesion Lesion 
Malay22(66.66%) 48.27±3.50 N=17 N=l6 
N=33 M22(66.66%), Chinesell(33.33%) (51.52%) (48.48%) 
Fll (33.33%) 
Ratio 1.7:1 
Table 2 
Showing provisionaVbistological diagnosis and IHC staining 
results 
no Provisional/clinical 
of samples diagnosis 
Benign Malignant 
N% No/o 
IHC staining with 
p53 antibodies 
N=33 20 13 17 16 28 5 
(60.60%)(39.39%) (51.51 %)(48.48%) (84.85%) (15.15%) 
1 1 
Table 3 
Showing clinical features, IHC pattern in malignant cases 
Total no Total +ve Primary/Secondary Clinical IHC 
of for features pattern 
samples malignancy +ve for 
p53 
staining 
LOW} 
LOA }8(50%) 
Cough} 
N=33 N=16 12 4 Haemoptysis 
(48.48%) (75%) (25%) 6(37.5%) 5(31.25%) 
SCC=7 SOB5(31.25%) 
Adeno Car=5 Fever3(18.75%) 
Smoker 
Asymptomatic 
2(12.5%) 
Table 4 
Showing p53 me positivity pattern in 5 positive cases 
Total no.ofpositive anti bodies used (No. +ve cells/ I 000) Histological 
cases % lliC +ve DOl 007 BP Phosphate 1801 diagnosis 
<20% 56 123 110 52 48 SCC(WD) 
N=5 <20% 415 238 185 177 240 Adeno Ca 
60% 652 365 672 -- ---- PDSCC 
<20 -- 410 350 -- ---- PDSCC 
<20 66 57 28 -- ---- MetGCT 
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Discussion 
The present study showed p53 expression was highest in 
squamous cell carcinoma ( 43.75°/o), followed by adeno 
carcinomas(3 1.25% )and metastatic lesions in lung ( 25°/o ).Of the 
five p53 antibodies used in the present study four were mutant 
forms namely DO 1 ,007 ,BP, 180 1 and the fith one phosphate was 
a phosphorylated p53 antibody. The five positive cases show 
strong reactivity with 007, BP; four out of five showed strong 
reactivity for DOl, two showed mild positivity for phosphate and 
1801 antibodies. The highest positivity of staining was found in 
two poorly differentiated carcinomas, followed by squamous cell 
carcinoma, adenocarcinomas and mild positivity by metastatic 
giant cell tumour. This finding indicates that p53 expression is 
different in different type of lung cancer and there is mutation in 
different axons. 
The finding of the present study is nearly similar to other study 
which using 007 a p53 mutant type of antibodies 
showed that the p53 staining was more in squamous cell 
13 
(epidermoid) carcinoma 16 of 27( 59.22% ), non small cell 
carcinoma 22 of 46( 4 7.8% ), small cell carcinoma 8 of 
30(26.6%), adenocarcinomas 6 of 19(37.57%)20• 
Other study showed over expression of p53 gene in pulmonary 
adenocarcinomas specifically associated with cigarettes smoking.21 
Over expression ofp53 tumour suppressor gene product in 
pulmonary adenocarcinomas has been found to be specifically 
associated with cigarrette smoking and represent a very early 
event in the genesis of the tumour. Mutations results in the 
overexpression and thus detectibility of the protein by IHC.p53 ... 
appears to have both a function as an oncoprotein perhaps by 
complexing in its mutant form with wild type p53 and as a tumour 
. . I 22 
suppressor gene In Its norma state . 
Although two cases were smoker in our study one was 
histologically diagnosed as well differentiated adenocarcinomas 
and the other poorly differentiated carcinoma. The poorly 
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differentiated carcinoma showed positive p53 staining while the 
well differentiated adenocarcinoma was negative. This is in partial 
concordance with the above mentioned studies. 
Clinico pathological studies of p53 abnormalities in present study 
showed 50o/o (8 of 16) of the malignant cases presented with loss of 
appetite(LOA), loss ofweight(LOW), 37.5%(6of 16) presented with 
haemoptysis c. d h . . 1 . 3 · 1ever an ot er constttuttona symptoms tn 
(18.75%) cases. 2 cases (12.5%) were smokers and 2(12.5%) 
cases were asymptomatic. Other studies showed conflicting 
results no correlation between p53 status and clinical 
presentations. 
P53 expression may play a role as a prognostic marker in lung 
cancer particularly non small cell lung cancer(NSCLC). In a study 
of 179 patients with NSCLC when correlated with p53 staining 
using D07 antibody showed patients with a strong expression of 
p53 oncoprotein(>SO%) have favourable prognostic factor leading 
to a prolong survival24• The median survival time for strong and 
weak p53 expression was more than 61/44 months respectively23 • 
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Literature review stated that in prostate carcinoma p53 immuno 
reactivity has been reported to be associated with higher Gleason 
score, nuclear grade, pathologic stage and metastasis. 25 
In head neck squamous carcinomas p53 immuno reactivity has 
been correlated with increased risk of local regional recurrences, 
resistance to radiotherapy and risk of developing a second primary 
tumour. 26In colorectal cancers it acts as an independent indicator of 
poor prognosis in some studies while in breast carcinoma lack of 
functional p53 is associated with aggressive biological factors and 
poor clinical out come.27 In melanomas p53 expression is 
associated with an increase in the depth of invasion in the primary 
tumours, presence of metastasis28• In thyroid malignancies p53 
reactivity is usually detected in anaplastic or poorly differentiated 
tumours.Normal thyroid does not express p53 mutations, while p53 
is present in low level in follicular adenoma(14%),nodular 
hyperplasia(l6.7%),papillary carcinoma (17%) indicates that p53 
does not have a major role in the pathogenesis of papillary 
16 
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carcinoma. 
But as our study was a retrospective one and because of the smaller 
sample size we could not study these parameters. 
P53 is a multifactorial molecule and regulates cell cycle, apoptosis, 
angiogenesis. In a study of 32 NSCLC it was found that 
expression of p53 and VEGF was higher in mutant p53 +ve 
tumours than those express normal p53 that showed no p53 
staining suggesting that the functional inactivation of p53 may up 
regulate VEGF expression. 30'31 '32 
It has been showed that introduction of wild type p53 into mutant 
p53 gene via recombinant technique had significantly suppresseQ. 
the VEGF protein expression. Also the expression of wild type p53 
can induce inhibition of growth of tumours formed in nude mice 
due to induction of apoptosis in tumour cells. Direct injection of 
tumour in terminal lung cancer patients with such expressing wild 
type p53 gave same result and in some cases leads to regression. 
These results suggest that p53 gene replacement may be 
applicable for the treatment of human cancer as an pro apototic and 
17 
anti angiogenic therapy33 As we only concentrated on p53 staining 
we could not correlate these findings. 
Conclusion: 
p53 is an important marker and p53 aberrations can have a role in 
diagnosis of neoplasia and could be employed to predict 
prognosis, recurrence and aggressiveness of the tumour in different 
sites like breast ,colon, melanoma, head and neck cancers, bladder 
and thyroid cancer etc. 
As literature search found little work done on lung samples in 
Malysia to detect expression of p53 oncogene, we thought it would 
be useful if we could do a base line study. We collected already 
existing lung samples in different histopathological laboratories 
in four teaching hospitals in Malaysia. We could only manage to 
get 33 lung samples covering different benign and malignant 
lesions and stained them with p53 antibodies and examined it 
under light microscope. 
We found that majority of the benign lung lesions does not 
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express p53, while a significant portion of malignant lesions"over ~~ 
express p53 mutant proteins. Although these findings are not 
statistically significant because of the low sample size still it can 
~+u.'KJL 0\1 lu.W() <S~ • .., ~ 
be used as a base line data for research in Malaysia. 
. A ~ 
Limitations: 
Inspite of our sincere effort to collect at least 100 lung samples we 
were able to get 60 lung samples from four different hospitals in 
Malaysia. Finally we could do p53 staining on only 33 samples, 
the rest 27 samples were not suitable for our study because of non 
availability of tissues after trimming. Also as this was a 
retrospective study using already available paraffin blocks of lung 
samples many areas of investigation like prognostic, behaviorial 
aspect of lung tumour were not possible to ascertain. 
A further study, both prospective and retrospective with larger 
number of lung samples is advocated to find out the importance 
ofp53 expression in lung carcinomas in terms of prognosis, 
behavior, recurrence, metastasis which will ultimately help better 
management, early diagnosis and influence the survival of lung 
19 
cancer patients. 
Also we advocate that lHC staining of biopsy samples using 
different antibodies should be used routinely alongside of H&E 
stain for better diagnosis of malignant lesions. 
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